Gilead/Kite team up with Pfizer for CAR-T-mAb combination – FierceBiotech
FierceBiotech |
Gilead/Kite team up with Pfizer for CAR–T-mAb combination
FierceBiotech Yescarta (axicabtagene ciloleucel), approved by the FDA last year in the first wave of new CAR–T cell therapies, will be teamed up with Pfizer's experimental humanized 4-1BB agonist utomilumab in patients with refractory large B-cell lymphoma. The … Kite Announces Clinical Collaboration to Evaluate Investigational Combination of Yescarta™ (Axicabtagene Ciloleucel … |
